clinical trial · NCT06830889
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·recruiting·n = 1,450
HER2-positive Breast CancerBL-M07D1T-DM1
brief summary
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.
started
Jun 3, 2025
primary completion
Oct 1, 2031
completion
Dec 1, 2031
last updated
Jan 22, 2026
official title
A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol